Delving into the Latest Updates on ESB-1609 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ESB 1609

Target

S1PRs

Action

agonists

Mechanism

S1PRs agonists(Sphingosine 1-phosphate receptors agonists)

Therapeutic Areas

Nervous System DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [1]

Active Indication-

Inactive Indication

Niemann-Pick Disease, Type C

Originator Organization

AbbVie, Inc.

Active Organization-

Inactive Organization

ESCAPE Bio, Inc.

License Organization

AbbVie, Inc.

ESCAPE Bio, Inc.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

A three-part, open-label, randomized (Part 1) and fixed-sequence (Part 2 and Part 3) study to compare the pharmacokinetics of different ESB1609 Form A formulations to that of ESB1609 Form B (Part 1) and to investigate the effect of CYP2C9 inhibition and induction on the single dose pharmacokinetics of ESB1609 Form A (Part 2 and Part 3). - CS0373-200169

Start Date20 Dec 2021

Sponsor / Collaborator

ESCAPE Bio, Inc.

NL-OMON55239

/ CompletedNot Applicable

A phase 1, randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and biomarker study of multiple ascending doses of ESB1609 in healthy volunteers. - CS0340 ESCAPE 190526

Start Date17 Feb 2020

Sponsor / Collaborator

ESCAPE Bio, Inc.

100 Clinical Results associated with ESB-1609

Login to view more data

100 Translational Medicine associated with ESB-1609

Login to view more data

100 Patents (Medical) associated with ESB-1609

Login to view more data

1

News (Medical) associated with ESB-1609

31 Mar 2021

·www.biospace.com

ESCAPE Bio to Present at Stifel’s 3rd Annual CNS Day

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- ESCAPE Bio Inc., a clinical stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, today announced that Paul Wren, Ph.D., Chief Scientific Officer of ESCAPE Bio, will participate in a fireside chat at Stifel’s 3rd Annual CNS Day on Thursday, April 1, 2021, at 3:30 p.m. ET. About ESCAPE Bio ESCAPE Bio is a clinical stage, privately held biopharmaceutical company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases. ESB1609 is in a Phase 1 multiple ascending dose study in healthy volunteers. ESCAPE has advanced a mutant-selective LRRK2 G2019S kinase inhibitor for Parkinson’s Disease (PD) patients to IND-enabling studies. A pharmacologic structure corrector of Alzheimer's patients carrying the ApoE4 risk allele is in Discovery. For additional information, please visit .

100 Deals associated with ESB-1609

Login to view more data